Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal

Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments

(2017) Justine Renard et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

(2017) Simon D Harding et al.   NUCLEIC ACIDS RESEARCH

Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors

(2017) Eva Martínez-Pinilla et al.   Frontiers in Pharmacology

Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings

(2016) Jose M. Trigo et al.   DRUG AND ALCOHOL DEPENDENCE

Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence

(2016) Jose M. Trigo et al.   Journal of Addiction Medicine

Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice

(2016) Angélica Pupin Schiavon et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Experimental design and analysis and their reporting: new guidance for publication in BJP

(2015) Michael J Curtis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP

(2015) John C McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor

(2015) R B Laprairie et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabinoid replacement therapy (CRT): Nabiximols (Sativex) as a novel treatment for cannabis withdrawal

(2015) DJ Allsop et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis

(2015) Margaret Haney et al.   NEUROPSYCHOPHARMACOLOGY

Cannabidiol as a Potential Treatment for Anxiety Disorders

(2015) Esther M. Blessing et al.   Neurotherapeutics

Molecular Targets of Cannabidiol in Neurological Disorders

(2015) Clementino Ibeas Bih et al.   Neurotherapeutics

Adverse Health Effects of Marijuana Use

(2014) Nora D. Volkow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal

(2014) David J. Allsop et al.   JAMA Psychiatry

Role of cannabinoid CB2receptor in the reinforcing actions of ethanol

(2013) Antonio Ortega-Álvaro et al.   ADDICTION BIOLOGY

Role of CB2 Cannabinoid Receptors in the Rewarding, Reinforcing and Physical Effects of Nicotine

(2013) Francisco Navarrete et al.   NEUROPSYCHOPHARMACOLOGY

A Brain on Cannabinoids: The Role of Dopamine Release in Reward Seeking

(2013) E. B. Oleson et al.   Cold Spring Harbor Perspectives in Medicine

The FAAH inhibitor URB597 efficiently reduces tyrosine hydroxylase expression through CB1- and FAAH-independent mechanisms

(2012) Barbara Bosier et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabidiol for the treatment ofcannabiswithdrawal syndrome: a case report

(2012) J. A. S. Crippa et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: Possible involvement of 5HT1A receptors

(2012) Alline Cristina Campos et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Decreased Cocaine Motor Sensitization and Self-Administration in Mice Overexpressing Cannabinoid CB2 Receptors

(2012) Auxiliadora Aracil-Fernández et al.   NEUROPSYCHOPHARMACOLOGY

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

(2012) A. C. Campos et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

(2012) F M Leweke et al.   Translational Psychiatry

Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice

(2011) Auxiliadora Aracil-Fernández et al.   ADDICTION BIOLOGY

Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour

(2011) Serena Deiana et al.   PSYCHOPHARMACOLOGY

Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers

(2010) Kenneth H. Levin et al.   DRUG AND ALCOHOL DEPENDENCE

Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research

(2010) Carol Kilkenny et al.   PLOS BIOLOGY

Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors

(2009) TV Zanelati et al.   BRITISH JOURNAL OF PHARMACOLOGY

Neurobiological mechanisms of cannabinoid addiction

(2008) L. Fattore et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

The orphan receptor GPR55 is a novel cannabinoid receptor

(2007) E Ryberg et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

(2007) A Thomas et al.   BRITISH JOURNAL OF PHARMACOLOGY

5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid

(2007) P. Massi et al.   JOURNAL OF NEUROCHEMISTRY